Nj State Employees Deferred Compensation Plan Mirati Therapeutics, Inc. Transaction History

Nj State Employees Deferred Compensation Plan

  • $800 Million
  • Q4 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 02, 2024
BUY
$41.99 - $62.38 $188,955 - $280,710
4,500 New
4,500 $264,000
Q4 2019

Jan 31, 2020
BUY
$70.76 - $128.86 $318,420 - $579,870
4,500 New
4,500 $580,000

Others Institutions Holding MRTX

# of Institutions
16
Shares Held
3.57M
Call Options Held
0
Put Options Held
36.6K
View Full List

About Mirati Therapeutics, Inc.

MRTX Quotes by TradingView
  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Nj State Employees Deferred Compensation Plan Portfolio

Follow Nj State Employees Deferred Compensation Plan and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nj State Employees Deferred Compensation Plan, based on Form 13F filings with the SEC.

News

Stay updated on Nj State Employees Deferred Compensation Plan with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email